5-tri-n-butylstannyl-5'-O-cyclosaligenyl-2'-deoxyuridine monophosphate | 1313031-75-2

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘧啶核苷酸
• 英文名称: 5-tri-n-butylstannyl-5'-O-cyclosaligenyl-2'-deoxyuridine monophosphate
• 英文别名: 1-[(2R,4S,5R)-4-hydroxy-5-[(2-oxo-4H-1,3,2lambda5-benzodioxaphosphinin-2-yl)oxymethyl]oxolan-2-yl]-5-tributylstannylpyrimidine-2,4-dione；1-[(2R,4S,5R)-4-hydroxy-5-[(2-oxo-4H-1,3,2λ5-benzodioxaphosphinin-2-yl)oxymethyl]oxolan-2-yl]-5-tributylstannylpyrimidine-2,4-dione
• CAS: 1313031-75-2
• 化学式: C₂₈H₄₃N₂O₈PSn
• 分子量: 685.342
• InChiKey: DZEKNABBIKDMCZ-GTEYPVIZSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.98
• 重原子数：
  40
• 可旋转键数：
  14
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.64
• 拓扑面积：
  124
• 氢给体数：
  2
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  5-tri-n-butylstannyl-5'-O-cyclosaligenyl-2'-deoxyuridine monophosphate 在 sodium iodide 、 双氧水 、 三氟乙酸 、 sodium hydroxide 作用下， 以 水 、 乙腈 为溶剂， 反应 0.25h， 生成 5-[(125)I]iodo-5'-O-cyclosaligenyl-2'-deoxyuridine monophosphate 、 5-[(125)I]iodo-5'-O-cyclosaligenyl-2'-deoxyuridine monophosphate
  参考文献：
  名称：

  Radiolabeled Cyclosaligenyl Monophosphates of 5-Iodo-2′-deoxyuridine, 5-Iodo-3′-fluoro-2′,3′-dideoxyuridine, and 3′-Fluorothymidine for Molecular Radiotherapy of Cancer: Synthesis and Biological Evaluation

  摘要：

  Targeted molecular radiotherapy opens unprecedented opportunities to eradicate cancer cells with minimal irradiation of normal tissues. Described in this study are radioactive cyclosaligenyl monophosphates designed to deliver lethal doses of radiation to cancer cells. These compounds can be radiolabeled with SPECT- and PET-compatible radionuclides as well as radionuclides suitable for Auger electron therapies. This characteristic provides an avenue for the personalized and comprehensive treatment strategy that comprises diagnostic imaging to identify sites of disease, followed by the targeted molecular radiotherapy based on the imaging results. The developed radiosynthetic methods produce no-carrier-added products with high radiochemical yield and purity. The interaction of these compounds with their target, butyrylcholinesterase, depends on the stereochemistry around the P atom. 1050 values are in the nanomolar range. In vitro studies indicate that radiation doses delivered to the cell nucleus are sufficient to kill cells of several difficult to treat malignancies including glioblastoma and ovarian and colorectal cancers.

  DOI：

  10.1021/jm201482p
• 作为产物：
  描述：

  2-chloro-4H-1,3,2-benzodioxaphosphorin 在 bis-triphenylphosphine-palladium(II) chloride 、 N,N-二异丙基乙胺 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 乙酸乙酯 、 N,N-二甲基甲酰胺 为溶剂， 反应 3.0h， 生成 5-tri-n-butylstannyl-5'-O-cyclosaligenyl-2'-deoxyuridine monophosphate 、
  参考文献：
  名称：

  [EN] TARGETED RADIOLABELED COMPOUNDS AND THEIR USE FOR THE TREATMENT AND DIAGNOSIS OF CANCER
  [FR] COMPOSÉS RADIOMARQUÉS CIBLÉS, ET LEUR UTILISATION POUR LE TRAITEMENT ET LE DIAGNOSTIC DU CANCER

  摘要：

  使用雄激素受体和/或丁酰胆碱酯酶靶向放射标记化合物的方法，例如环萨林基嘌呤核苷酸单磷酸，用于癌症的治疗和诊断。

  公开号：

  WO2011079245A1

文献信息

• [EN] TARGETED RADIOLABELED COMPOUNDS AND THEIR USE FOR THE TREATMENT AND DIAGNOSIS OF CANCER<br/>[FR] COMPOSÉS RADIOMARQUÉS CIBLÉS, ET LEUR UTILISATION POUR LE TRAITEMENT ET LE DIAGNOSTIC DU CANCER
  申请人：UNIV NEBRASKA

  公开号：WO2011079245A1

  公开（公告）日：2011-06-30

  Method of using androgen receptor and/or butyrylcholinesterase targeted radiolabeled compounds, e.g., cycloSalingenyl pyrimidine nucleoside monophosphates, for the treatment and diagnosis of cancer.

  使用雄激素受体和/或丁酰胆碱酯酶靶向放射标记化合物的方法，例如环萨林基嘌呤核苷酸单磷酸，用于癌症的治疗和诊断。
• Radiolabeled Cyclosaligenyl Monophosphates of 5-Iodo-2′-deoxyuridine, 5-Iodo-3′-fluoro-2′,3′-dideoxyuridine, and 3′-Fluorothymidine for Molecular Radiotherapy of Cancer: Synthesis and Biological Evaluation
  作者：Zbigniew P. Kortylewicz、Yu Kimura、Kotaro Inoue、Elizabeth Mack、Janina Baranowska-Kortylewicz

  DOI：10.1021/jm201482p

  日期：2012.3.22

  Targeted molecular radiotherapy opens unprecedented opportunities to eradicate cancer cells with minimal irradiation of normal tissues. Described in this study are radioactive cyclosaligenyl monophosphates designed to deliver lethal doses of radiation to cancer cells. These compounds can be radiolabeled with SPECT- and PET-compatible radionuclides as well as radionuclides suitable for Auger electron therapies. This characteristic provides an avenue for the personalized and comprehensive treatment strategy that comprises diagnostic imaging to identify sites of disease, followed by the targeted molecular radiotherapy based on the imaging results. The developed radiosynthetic methods produce no-carrier-added products with high radiochemical yield and purity. The interaction of these compounds with their target, butyrylcholinesterase, depends on the stereochemistry around the P atom. 1050 values are in the nanomolar range. In vitro studies indicate that radiation doses delivered to the cell nucleus are sufficient to kill cells of several difficult to treat malignancies including glioblastoma and ovarian and colorectal cancers.